STATegics, Inc.

Organization Address
428 Oakmead Pkwy
Sunnyvale, CA 94085


Biotech and Pharmaceutical

Organization Description

STATegics, Inc. is a privately-held biopharmaceutical company in South San Francisco, CA, committed to the discovery and development of small molecule modulators of cytokine receptors. The company’s lead programs are focused on small molecule agonists of erythropoietin (EPO) and thrombopoietin (TPO) receptors for the treatment of central nervous system diseases and thrombocytopenia, respectively. STATegics’ lead compounds are selective agonists of the tissue-protective EPO receptor. They have drug-like physical properties for development and have demonstrated promising in vivo effects for the treatment of Friedreich’s ataxia, an orphan neurodegenerative disease with no treatments currently available, Parkinson’s disease, and acute kidney injury, a sudden loss of kidney function associated with significant morbidity and mortality. STATegics is also developing screening technologies for efficient and rapid identification of small molecules targeting allosteric sites of cytokine receptors.